TENAX THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $TENX in the last 7 days.
Tenax Therapeutics (TENX) paused LEVEL-2 enrollment to update inclusion criteria based on Phase 3 LEVEL trial results. The company aims to target sicker PH-HFpEF patients after seeing benefits in this subgroup. Tenax plans to seek FDA feedback and updated its investor presentation. The pause is not related to safety concerns.
Doogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.
Giordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.
Recent TENX coverage spans insider activity, financial news and technology.
In the last 30 days, TENX insiders filed 2 SEC Form 4 transactions — 2 purchases ($111K) and no sales. The most active reporter was Doogan Declan with 1 filing.
The enrollment pause signals a delay in trial progress and may dampen near‑term investor sentiment.
Insider purchase may signal confidence, modest upside potential.
Small insider purchase signals confidence but limited market impact due to modest size.
Small insider purchase may signal confidence but limited market impact due to modest size.
The loss of a large institutional holder may pressure TENX price modestly.
AlphAI scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tenax Therapeutics (TENX) paused LEVEL-2 enrollment to update inclusion criteria based on Phase 3 LEVEL trial results. The company aims to target sicker PH-HFpEF patients after seeing benefits in this subgroup. Tenax plans to seek FDA feedback and updated its investor presentation. The pause is not related to safety concerns.
1 min readDoogan Declan purchased 53,000 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.92 ($0.10M total) on 2026-09-16.
1 min readGiordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.
1 min readSTAAB THOMAS R II (Chief Financial Officer) purchased 5,675 shares of TENAX THERAPEUTICS, INC. (TENX) at $1.94 on 2026-09-11.
1 min readING Groep N.V. and ING Capital Markets LLC filed an amended Schedule 13G/A, disclosing zero ownership in Tenax Therapeutics (TENX) as of September 11, 2026. The filing indicates no voting or dispositive power over Tenax's common stock, with 37,423,917 shares outstanding as of July 28, 2026.
1 min readADAR1 Capital Management, LLC purchased 900,000 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at $1.78 ($1.60M total) on 2026-09-03. Filed jointly with Schneeberger Daniel (10% owner).
1 min readADAR1 Capital Management and its manager, Daniel Schneeberger, reported a 14% stake in Tenax Therapeutics (TENX), owning 5,257,389 shares as of July 28, 2026. They also hold warrants for additional shares, excluded due to a 4.99% ownership cap.
2 min readTenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.
2 min readADAR1 Capital Management, LLC, a 10% owner of Tenax Therapeutics (TENX), reported buying 770,333 shares of common stock from August 31 to September 2, 2026, at an average price of $1.79 per share, ranging from $1.77 to $1.80. The purchases were made indirectly through private investment funds managed by ADAR1.
1 min readADAR1 Capital Management, LLC purchased 770,333 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.79 ($1.79–$1.80, $1.38M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Schneeberger Daniel (10% owner).
1 min read
